Related Experiment Videos
[Plaque stabilization by LDL apheresis?]
1Institut für Klinische Chemie und Pathobiochemie, Medizinische Fakultät, Universität Rostock. pschuffw@med.uni-rostock.de
Insights
Extracorporeal LDL-elimination rapidly stabilizes vulnerable plaques, significantly reducing atherothrombotic events like myocardial infarction. This LDL-apheresis therapy offers earlier clinical event reduction compared to drug therapy alone.
Area of Science:
- Cardiovascular Medicine
- Lipid Metabolism
- Interventional Cardiology
Context:
- Vulnerable lipid-rich plaques are primary drivers of atherothrombotic events, including unstable angina and acute myocardial infarction.
- Long-term low-density lipoprotein (LDL)-lowering therapies demonstrably stabilize plaques and reduce myocardial reinfarction rates.
- Emerging evidence suggests extracorporeal LDL-elimination may offer earlier clinical event reduction than drug therapy alone.
Purpose:
- To investigate the early effects of LDL-apheresis on vulnerable plaque regression and atherothrombotic event reduction.
- To elucidate the mechanisms by which LDL-apheresis impacts plaque stability, vascular resistance, and coagulation.
- To compare the efficacy of LDL-apheresis with conventional LDL-lowering drug therapy in managing high-risk cardiovascular patients.
Summary:
- Regular extracorporeal LDL-elimination, achieving over 60% LDL reduction weekly, is associated with early regression of lipid-rich vascular lesions.
- LDL-apheresis, particularly HELP and double filtration methods, reduces plasma viscosity and improves vasomotoric reserve, lowering peripheral arterial resistance and shear-stress on vulnerable plaques.
- This procedure effectively removes oxidized LDL, mitigating inflammatory effects that hinder plaque stabilization, and normalizes hypercoagulable states by interacting with coagulation factors, thereby preventing atherothrombotic events.
Impact:
- LDL-apheresis demonstrates potential for rapid plaque stabilization and significant reduction in atherothrombotic events, offering a promising therapeutic option for high-risk cardiovascular patients.
- The early regression of lipid-rich lesions observed with LDL-apheresis suggests a faster therapeutic benefit compared to traditional long-term LDL-lowering strategies.
- By addressing multiple pathophysiological mechanisms including LDL levels, inflammation, vascular resistance, and coagulation, LDL-apheresis provides a comprehensive approach to preventing recurrent cardiovascular events.
Abstract:
Vulnerable lipid-rich plaques are often the cause of atherothrombotic events leading to unstable angina and/or to acute myocardial infarction. Consequent long-term LDL-lowering by drugs as shown by the most important intervention studies lead to plaque stabilization as shown by the significant reduction of myocardial reinfarction. First studies in patients undergoing regular extracorporeal LDL-elimination indicate, that clinical events might be reduced much earlier as by drug therapy alone: A more than 60% reduction of LDL at weekly intervals is obviously associated with an early regression of lipid-rich vascular lesions. LDL-apheresis, mainly by HELP and by double filtration reduces the shear-stress of the flowing blood on vulnerable plaques either by its effect on plasmaviscosity and/or on the vasomotoric reserve thus leading to a lower peripheral arterial resistance. Furthermore oxidized LDL, which might counteract plaque stabilisation by its inflammatory effects are effectively eliminated by LDL-apheresis. The affinity of different LDL-apheresis procedures to coagulation factors normalizes hypercoagulatory states thus avoiding atherothrombotic events at the site of vulnerable or erosive plaques.